Related Experiment Video
Updated: Jul 8, 2025

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Cardiomyopathy in cirrhosis: From pathophysiology to clinical care
Hongqun Liu1, Jwan A Naser2, Grace Lin2
1Liver Unit, University of Calgary Cumming School of Medicine, Calgary, AB, Canada.
Insights
Cirrhotic cardiomyopathy (CCM) involves heart dysfunction in cirrhosis patients, impacting outcomes. Understanding its mechanisms and refining diagnostic criteria are key for improved patient management and treatment strategies.
Area of Science:
- Cardiology
- Hepatology
- Internal Medicine
Background:
- Cirrhotic cardiomyopathy (CCM) is heart dysfunction in cirrhosis patients, affecting prognosis.
- Pathophysiology involves portal hypertension and hepatocellular insufficiency.
- Diagnostic criteria have evolved, with recent updates focusing on systolic and diastolic function.
Purpose of the Study:
- To review the pathogenesis and pathophysiology of CCM.
- To discuss clinical implications and diagnostic advancements.
- To explore potential treatment strategies for CCM.
Main Methods:
- Review of existing literature on CCM pathogenesis, diagnosis, and treatment.
- Comparison of diagnostic criteria (2005 vs. 2019 Consortium).
- Discussion of cardiac imaging modalities (echocardiography, MRI) and exercise challenges.
Main Results:
- CCM contributes to increased mortality after interventions like liver transplantation.
- CCM plays a role in hepatorenal syndrome development.
- Advances in imaging and diagnostic criteria refine CCM evaluation.
Conclusions:
- CCM is a significant complication of cirrhosis with complex pathophysiology.
- Improved diagnostic tools are crucial for accurate CCM assessment.
- While no definitive therapy exists, research into potential treatments is ongoing.
Abstract:
Cirrhotic cardiomyopathy (CCM) is defined as systolic or diastolic dysfunction in the absence of prior heart disease or another identifiable cause in patients with cirrhosis, in whom it is an important determinant of outcome. Its underlying pathogenic/pathophysiological mechanisms are rooted in two distinct pathways: 1) factors associated with portal hypertension, hyperdynamic circulation, gut bacterial/endotoxin translocation and the resultant inflammatory phenotype; 2) hepatocellular insufficiency with altered synthesis or metabolism of substances such as proteins, lipids, carbohydrates, bile acids and hormones. Different criteria have been proposed to diagnose CCM; the first in 2005 by the World Congress of Gastroenterology, and more recently in 2019 by the Cirrhotic Cardiomyopathy Consortium. These criteria mainly utilised echocardiographic evaluation, with the latter refining the evaluation of diastolic function and integrating global longitudinal strain into the evaluation of systolic function, an important addition since the haemodynamic changes that occur in advanced cirrhosis may lead to overestimation of systolic function by left ventricular ejection fraction. Advances in cardiac imaging, such as cardiac magnetic resonance imaging and the incorporation of an exercise challenge, may help further refine the diagnosis of CCM. Over recent years, CCM has been shown to contribute to increased mortality and morbidity after major interventions, such as liver transplantation and transjugular intrahepatic portosystemic shunt insertion, and to play a pathophysiologic role in the genesis of hepatorenal syndrome. In this review, we discuss the pathogenesis/pathophysiology of CCM, its clinical implications, and the role of cardiac imaging modalities including MRI. We also compare diagnostic criteria and review the potential diagnostic role of electrocardiographic QT prolongation. At present, no definitive medical therapy exists, but some promising potential treatment strategies for CCM are reviewed.
More Related Videos
09:37Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats
Published on: August 1, 2018
04:00Laparoscopic Splenectomy with Pericardial Devascularization for Hypersplenism and Esophageal Variceal Hemorrhage Due to Portal Hypertension
Published on: November 15, 2024
Related Concept Videos
Pathophysiology of Heart Failure
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Esophageal Varices-I: Introduction